[18F] FDG-PET findings associated with cognitive impairment if multiple system atrophy
Objective: To explore the cortical metabolic pattern associated with cognitive impairment in multiple system atrophy (MSA). Background: Cognitive impairment (CI) has been increasingly recognized in…Dyskinesia Rates in Patients with Parkinson’s Disease on CVT-301 (levodopa inhalation powder)
Objective: Analysis of dyskinesia as reported by PD diary, adverse events, UPDRS part IV dyskinesia score and examiner rated observation, during a phase 3 study…Prevalence and predisposing factors of Parkinson disease: A barangay community-based study in Quezon, Philippines
Objective: The researchers aim to determine the prevalence of the Parkinson Disease in a locale and explore the possible predisposing factors on the development of…Assessing Tele-Health Outcomes in Multiyear Extensions of Parkinson’s Disease Trials (AT-HOME PD): An Update on Recruitment
Objective: To leverage technology to develop a new model for the long-term follow-up of Parkinson’s disease (PD) clinical trial cohorts and investigate novel disease measures.…Is safinamide helpful in multiple system atrophy?
Objective: To retrospectively review the clinical benefit of safinamide in patients with Multiple System Atrophy. Background: Safinamide is a new monoamine oxidase-B inhibitor, with dopaminergic…Quantifying eye and gait abnormalities in Parkinson’s patients after Deep brain stimulation
Objective: To examine the usefulness of precise measurements of gait and eye movements as a means of quantifying PD. The aim is to identify and…Using Quantitative Susceptibility Mapping to Predict Dementia in Parkinson’s Disease
Objective: To investigate how brain iron deposition relates to visual function and dementia risk in Parkinson’s Disease (PD). Background: Oxidative stress due to brain iron…Amylin single-nucleotide polymorphism and Parkinson’s disease
Objective: The objective of this study was to evaluate if a single nucleotide polymorphism (SNP) in the amylin sequence is present in patients with Parkinson’s…Measuring progression of nigrostriatal degeneration in Parkinson’s disease using 18F-AV-133 vesicular monoamine transporter type-2 (VMAT2) PET
Objective: To evaluate the progression of nigrostriatal degeneration in participants with Parkinson’s disease (PD) using 18F-AV-133 vesicular monoamine transporter type-2 (VMAT2) PET. Background: Vesicular monoamine…Clinical features of constipation in patients with Parkinson’s disease: a cross-sectional study in China
Objective: This study was designed to explore the clinical features of constipation, and investigate the risk factors of constipation in Chinese PD patients. Background: Constipation…
- « Previous Page
- 1
- …
- 194
- 195
- 196
- 197
- 198
- …
- 217
- Next Page »